Jiming Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiming Fang has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Moira K. Kapral
ICES, Toronto, Ontario, Canada
24 shared publications - Peter C. Austin
University of Toronto
22 shared publications - Amy Ying Xin Yu
ICES, Toronto, Ontario, Canada
15 shared publications - Manav Vyas
University of Toronto
10 shared publications - Dennis T. Ko
University of Toronto, Toronto, ON, Canada
7 shared publications - Douglas S. Lee
University of Toronto
7 shared publications
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218554
Long-Term Risk of Dementia After TIA
Background and ObjectivesLong-term risk of dementia after TIA remains poorly characterized, despite a known impact on cognition. We aimed to quantify the rate, relative risk, and time course of inc...
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218554
Long-Term Risk of Dementia After TIA
Background and ObjectivesLong-term risk of dementia after TIA remains poorly characterized, despite a known impact on cognition. We aimed to quantify the rate, relative risk, and time course of inc...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218543
Association Between Immigration Status and the Intensity of Acute Stroke Care in Ontario, Canada
Background and ObjectivesImmigration status is associated with stroke incidence and outcomes; however, its association with admission to and length of stay in the intensive care unit (ICU) in patie...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218543
Association Between Immigration Status and the Intensity of Acute Stroke Care in Ontario, Canada
Background and ObjectivesImmigration status is associated with stroke incidence and outcomes; however, its association with admission to and length of stay in the intensive care unit (ICU) in patie...
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2780-2788
Sex Differences in Screening for Large Vessel Occlusion and Thrombectomy: A Population-Based Cohort Study
BACKGROUND: Population-based sex differences in large vessel occlusion (LVO) screening and thrombectomy use for acute ischemic stroke are not well understood. We compared the detection of LVO, thrombectomy use, and long-term clinical outcomes in female versus male patients with cerebral ischemia in Ontario, Canada. METHODS: This retrospective cohort study used data from the Ontario Stroke Registry linked with health administrative data. We included adult patients hospitalized for cerebral ischemia within the first 24 hours of last seen normal time during 2 fiscal years (2019/2020 and 2022/2023). We used modified Poisson regression models to evaluate sex differences in intracranial neurovascular imaging, thrombolysis, or thrombectomy. Among patients with LVO, we used Cox proportional hazard and cause-specific hazard models to compare female versus male patients long-term mortality, readmission, or nursing home admission until 2025, stratified by thrombectomy treatment. RESULTS: Among 16 935 eligible patients (47% female patients; median age, 76 [interquartile range, 65–84] years), female patients were less likely than male patients to receive intracranial neurovascular imaging (83.6% female versus 87.8% male; P P <0.01). Thrombectomy use was higher in female patients than male patients in the overall cohort (adjusted relative risk, 1.08 [1.01–1.16]), but, once restricted to those with LVO, thrombectomy use was similar (adjusted relative risk, 0.98 [0.93–1.03]). Adjusted hazard of the composite outcome was lower in female patients with LVO treated with thrombectomy compared with their male counterparts (adjusted hazard ratio, 0.88 [0.77–0.99]). CONCLUSIONS: Female patients with acute cerebral ischemia were less likely than male patients to receive intracranial neurovascular imaging but more likely to have an LVO, and long-term mortality was lower in female patients with LVO treated with thrombectomy. Stroke outcomes’ research must account for neurovascular imaging and LVO status to accurately identify sex-based disparities in stroke care and outcomes.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2780-2788
Open AccessSex Differences in Screening for Large Vessel Occlusion and Thrombectomy: A Population-Based Cohort Study
BACKGROUND: Population-based sex differences in large vessel occlusion (LVO) screening and thrombectomy use for acute ischemic stroke are not well understood. We compared the detection of LVO, thrombectomy use, and long-term clinical outcomes in female versus male patients with cerebral ischemia in Ontario, Canada. METHODS: This retrospective cohort study used data from the Ontario Stroke Registry linked with health administrative data. We included adult patients hospitalized for cerebral ischemia within the first 24 hours of last seen normal time during 2 fiscal years (2019/2020 and 2022/2023). We used modified Poisson regression models to evaluate sex differences in intracranial neurovascular imaging, thrombolysis, or thrombectomy. Among patients with LVO, we used Cox proportional hazard and cause-specific hazard models to compare female versus male patients long-term mortality, readmission, or nursing home admission until 2025, stratified by thrombectomy treatment. RESULTS: Among 16 935 eligible patients (47% female patients; median age, 76 [interquartile range, 65–84] years), female patients were less likely than male patients to receive intracranial neurovascular imaging (83.6% female versus 87.8% male; P P <0.01). Thrombectomy use was higher in female patients than male patients in the overall cohort (adjusted relative risk, 1.08 [1.01–1.16]), but, once restricted to those with LVO, thrombectomy use was similar (adjusted relative risk, 0.98 [0.93–1.03]). Adjusted hazard of the composite outcome was lower in female patients with LVO treated with thrombectomy compared with their male counterparts (adjusted hazard ratio, 0.88 [0.77–0.99]). CONCLUSIONS: Female patients with acute cerebral ischemia were less likely than male patients to receive intracranial neurovascular imaging but more likely to have an LVO, and long-term mortality was lower in female patients with LVO treated with thrombectomy. Stroke outcomes’ research must account for neurovascular imaging and LVO status to accurately identify sex-based disparities in stroke care and outcomes.
- Open Access
- 11 August 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 114
Therapeutic plasma exchange in people with multiple sclerosis: A province-wide study
- 11 August 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 114
Open AccessTherapeutic plasma exchange in people with multiple sclerosis: A province-wide study
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e038402
Individual and County‐Level Social Determinants of Health and Acute Reperfusion Therapies: Get With The Guidelines‐Stroke Registry Results
Background: The associations between individual‐ and county‐level social determinants of health and reperfusion therapies (thrombolysis or thrombectomy) for acute ischemic stroke have been described separately, but they are rarely studied together. Methods and Results: We identified 1.5 million patients aged ≥40 years with acute ischemic stroke between January 1, 2015 and December 31, 2019 from the Get With The Guidelines‐Stroke registry in the United States. We ascertained age, sex, rural residence, and ethnicity or race at the individual level, and poverty, unemployment, and lower education (defined as less than high school) at the county level. We used multivariable log‐binomial regression models estimated using generalized estimating equations methods to account for county‐level clustering and adjusted for comorbidities. About 13.4% (n=203 800) patients received reperfusion therapy. Black (adjusted risk ratio [aRR, 1.06 [95% CI, 1.04–1.07]) and Hispanic (aRR, 1.36 [95% CI, 1.33–1.40]) patients were more likely to receive it compared with White patients, as were those in counties with lower education (aRR, 1.08 [95% CI, 1.07–1.09]). Older adults (5‐year increase in age aRR, 97 [95% CI, 0.97–0.97]), rural residents (aRR, 0.58 [95% CI, 0.56–0.59]), and those with missing last known well time (aRR, 0.30 [95% CI, 0.29–0.30]) were less likely to receive it. Missing last known well was less likely in Hispanic (aRR, 0.94 [95% CI, 0.92–0.95]) and Asian (aRR, 0.93 [95% CI, 0.90–0.96]) patients compared with White patients and more likely in those residing in counties with high unemployment (aRR, 1.07 [95% CI, 1.06–1.08]). Conclusions: Individual‐ and county‐level social determinants of health were associated with reperfusion therapies and missing last known well times. Understanding the mechanisms by which these factors could affect treatment eligibility through time‐based criteria can help increase reperfusion therapies for all.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e038402
Open AccessIndividual and County‐Level Social Determinants of Health and Acute Reperfusion Therapies: Get With The Guidelines‐Stroke Registry Results
Background: The associations between individual‐ and county‐level social determinants of health and reperfusion therapies (thrombolysis or thrombectomy) for acute ischemic stroke have been described separately, but they are rarely studied together. Methods and Results: We identified 1.5 million patients aged ≥40 years with acute ischemic stroke between January 1, 2015 and December 31, 2019 from the Get With The Guidelines‐Stroke registry in the United States. We ascertained age, sex, rural residence, and ethnicity or race at the individual level, and poverty, unemployment, and lower education (defined as less than high school) at the county level. We used multivariable log‐binomial regression models estimated using generalized estimating equations methods to account for county‐level clustering and adjusted for comorbidities. About 13.4% (n=203 800) patients received reperfusion therapy. Black (adjusted risk ratio [aRR, 1.06 [95% CI, 1.04–1.07]) and Hispanic (aRR, 1.36 [95% CI, 1.33–1.40]) patients were more likely to receive it compared with White patients, as were those in counties with lower education (aRR, 1.08 [95% CI, 1.07–1.09]). Older adults (5‐year increase in age aRR, 97 [95% CI, 0.97–0.97]), rural residents (aRR, 0.58 [95% CI, 0.56–0.59]), and those with missing last known well time (aRR, 0.30 [95% CI, 0.29–0.30]) were less likely to receive it. Missing last known well was less likely in Hispanic (aRR, 0.94 [95% CI, 0.92–0.95]) and Asian (aRR, 0.93 [95% CI, 0.90–0.96]) patients compared with White patients and more likely in those residing in counties with high unemployment (aRR, 1.07 [95% CI, 1.06–1.08]). Conclusions: Individual‐ and county‐level social determinants of health were associated with reperfusion therapies and missing last known well times. Understanding the mechanisms by which these factors could affect treatment eligibility through time‐based criteria can help increase reperfusion therapies for all.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 3090-3094
Association Between Schizophrenia and Adherence to Medications for Secondary Stroke Prevention
BACKGROUND: Schizophrenia is associated with an increased risk of stroke and under-treatment of vascular risk factors, but less is known about adherence to medications for secondary stroke prevention. We sought to understand current rates of adherence to secondary stroke prevention therapies among elderly ischemic stroke survivors with and without schizophrenia. METHODS: In a population-based cohort study, we used administrative databases to identify all patients aged ≥65 years who were hospitalized with ischemic stroke in the province of Ontario, Canada, between 2004 and 2018, and a validated algorithm to identify those with schizophrenia. Among patients who filled a prescription for antihypertensive, lipid-lowering, or anticoagulant medications within 3 months and were alive 1 year after discharge, we compared the proportion with low adherence (defined as an annual proportion of days covered of <0.4) in those with and without schizophrenia. We used multivariable logistic regression to estimate the association between schizophrenia and low adherence adjusting for age, sex, comorbid conditions, area of residence, and socioeconomic status. RESULTS: Of the 55 842 patients included, the mean age was 79.5 years, 53.3% were women, and 1.0% had schizophrenia. Among those who survived to 1 year after discharge, individuals with schizophrenia were more likely than those without to have low adherence to antihypertensive (28.0% versus 18.8%; adjusted odds ratio, 1.60 [95% CI, 1.28–2.01]), lipid-lowering (38.6% versus 29.8%; adjusted odds ratio, 1.60 [95% CI, 1.31–1.96]), or anticoagulant medications (41.1% versus 32.0%; adjusted odds ratio, 1.61 [95% CI, 1.00–2.58]), even after adjustment for age, sex, comorbid illness, rurality, and neighborhood income quintile. CONCLUSIONS: Schizophrenia is associated with poor adherence to medications for secondary stroke prevention. Future work should focus on developing individual- and system-level interventions to improve vascular risk factor management in this population.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 3090-3094
Association Between Schizophrenia and Adherence to Medications for Secondary Stroke Prevention
BACKGROUND: Schizophrenia is associated with an increased risk of stroke and under-treatment of vascular risk factors, but less is known about adherence to medications for secondary stroke prevention. We sought to understand current rates of adherence to secondary stroke prevention therapies among elderly ischemic stroke survivors with and without schizophrenia. METHODS: In a population-based cohort study, we used administrative databases to identify all patients aged ≥65 years who were hospitalized with ischemic stroke in the province of Ontario, Canada, between 2004 and 2018, and a validated algorithm to identify those with schizophrenia. Among patients who filled a prescription for antihypertensive, lipid-lowering, or anticoagulant medications within 3 months and were alive 1 year after discharge, we compared the proportion with low adherence (defined as an annual proportion of days covered of <0.4) in those with and without schizophrenia. We used multivariable logistic regression to estimate the association between schizophrenia and low adherence adjusting for age, sex, comorbid conditions, area of residence, and socioeconomic status. RESULTS: Of the 55 842 patients included, the mean age was 79.5 years, 53.3% were women, and 1.0% had schizophrenia. Among those who survived to 1 year after discharge, individuals with schizophrenia were more likely than those without to have low adherence to antihypertensive (28.0% versus 18.8%; adjusted odds ratio, 1.60 [95% CI, 1.28–2.01]), lipid-lowering (38.6% versus 29.8%; adjusted odds ratio, 1.60 [95% CI, 1.31–1.96]), or anticoagulant medications (41.1% versus 32.0%; adjusted odds ratio, 1.61 [95% CI, 1.00–2.58]), even after adjustment for age, sex, comorbid illness, rurality, and neighborhood income quintile. CONCLUSIONS: Schizophrenia is associated with poor adherence to medications for secondary stroke prevention. Future work should focus on developing individual- and system-level interventions to improve vascular risk factor management in this population.
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e041185
Association of Albuminuria With 1‐Year Risk of Heart Failure and Other Adverse Outcomes in Atrial Fibrillation
Background: Albuminuria is associated with increased stroke risk in atrial fibrillation (AF), but its relationship with heart failure (HF) and other adverse outcomes in AF is less well understood. Methods: Using linked administrative databases, we conducted a retrospective cohort study of individuals aged ≥66 years who were newly diagnosed with AF between April 2009 and March 2019 in Ontario, Canada. Albuminuria was assessed using (1) urine albumin‐to‐creatinine ratio (UACR, mg/g) and (2) dipstick proteinuria (negative, trace, 1+, 2+, ≥3+). Cause‐specific hazards regression estimated adjusted hazard ratios (HRs) for HF hospitalizations or emergency department visits, stroke hospitalizations, bleeding hospitalizations, and death over 1 year. Results: We included 64 717 individuals with UACR data and 110 430 with dipstick proteinuria data. Relative to UACR 5 mg/g, the HRs for UACR 30 mg/g (below the microalbuminuria threshold) were 1.39 (95% CI, 1.28–1.50) for HF, 1.22 (95% CI, 1.07–1.40) for bleeding, and 1.35 (95% CI, 1.27–1.42) for death. A UACR of 30 mg/g versus 5 mg/g was associated with an HR of 1.16 (95% CI, 0.99–1.36) for stroke but the HR was significantly elevated at UACR values ≥65 mg/g. Increasing dipstick proteinuria was also associated with increases in the HR for adverse outcomes. A UACR of 30 mg/g was associated with greater HF risk (versus 5 mg/g) than all CHA₂DS₂VASc components except age >75 years and prior HF. Conclusions: Albuminuria is associated with increased hazards of HF, stroke, bleeding, and death in patients with AF even at low UACR levels. Albuminuria may enhance risk stratification in AF beyond traditional scores.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e041185
Open AccessAssociation of Albuminuria With 1‐Year Risk of Heart Failure and Other Adverse Outcomes in Atrial Fibrillation
Background: Albuminuria is associated with increased stroke risk in atrial fibrillation (AF), but its relationship with heart failure (HF) and other adverse outcomes in AF is less well understood. Methods: Using linked administrative databases, we conducted a retrospective cohort study of individuals aged ≥66 years who were newly diagnosed with AF between April 2009 and March 2019 in Ontario, Canada. Albuminuria was assessed using (1) urine albumin‐to‐creatinine ratio (UACR, mg/g) and (2) dipstick proteinuria (negative, trace, 1+, 2+, ≥3+). Cause‐specific hazards regression estimated adjusted hazard ratios (HRs) for HF hospitalizations or emergency department visits, stroke hospitalizations, bleeding hospitalizations, and death over 1 year. Results: We included 64 717 individuals with UACR data and 110 430 with dipstick proteinuria data. Relative to UACR 5 mg/g, the HRs for UACR 30 mg/g (below the microalbuminuria threshold) were 1.39 (95% CI, 1.28–1.50) for HF, 1.22 (95% CI, 1.07–1.40) for bleeding, and 1.35 (95% CI, 1.27–1.42) for death. A UACR of 30 mg/g versus 5 mg/g was associated with an HR of 1.16 (95% CI, 0.99–1.36) for stroke but the HR was significantly elevated at UACR values ≥65 mg/g. Increasing dipstick proteinuria was also associated with increases in the HR for adverse outcomes. A UACR of 30 mg/g was associated with greater HF risk (versus 5 mg/g) than all CHA₂DS₂VASc components except age >75 years and prior HF. Conclusions: Albuminuria is associated with increased hazards of HF, stroke, bleeding, and death in patients with AF even at low UACR levels. Albuminuria may enhance risk stratification in AF beyond traditional scores.
- 1 June 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (6) , 765-774
Risk for Stroke After Newly Diagnosed Atrial Fibrillation During Hospitalization for Other Primary Diagnoses
Atrial fibrillation (AF) that is first diagnosed during hospitalization for other causes can subside with resolution of the inciting stressor. To describe the risk for stroke after newly diagnosed AF during hospitalization for other causes. Population-based retrospective cohort study. Ontario, Canada. Patients aged 66 years or older discharged alive from the hospital between April 2013 and March 2023 with a first diagnosis of AF. Newly diagnosed AF during hospitalization for other causes, categorized into cardiac medical, noncardiac medical, cardiac surgical, and noncardiac surgical. The primary outcome was hospitalization for stroke. The cumulative incidence function was used to estimate crude incidence, censoring on anticoagulant dispensation. Inverse probability of censoring weights were used to account for informative censoring. Atrial fibrillation was diagnosed in 20 639 patients (mean age, 77.1 years; 58.1% male) while hospitalized for other causes: 8340 (40.4%) for noncardiac medical, 7097 (34.4%) for cardiac surgical, 3553 (17.2%) for noncardiac surgical, and 1649 (8.0%) for cardiac medical diagnoses. At 1 year, anticoagulants were being dispensed to 26.4% of patients with CHA2DS2-VA scores of 1 to 4 and 35.2% of those with CHA2DS2-VA scores of 5 to 8. The 1-year risk for stroke without anticoagulation was 1.3% (95% CI, 0.7% to 2.3%) for cardiac medical, 1.2% (CI, 0.9% to 1.5%) for noncardiac medical, 1.1% (CI, 0.8% to 1.7%) for noncardiac surgical, and 1.0% (CI, 0.7% to 1.3%) for cardiac surgical patients. Patients with CHA2DS2-VA scores of 1 to 4 had a 1-year stroke risk of 0.7% (CI, 0.6% to 1.0%) without anticoagulation, compared with 1.8% (CI, 1.4% to 2.2%) at CHA2DS2-VA scores of 5 to 8. Long-standing AF may have been misclassified as newly diagnosed, leading to overestimation of stroke risk. Among patients with newly diagnosed AF during hospitalization for other causes, a substantial proportion with low CHA2DS2-VA scores receive anticoagulation, with modest increases in this proportion at higher scores. The stroke risk in patients with CHA2DS2-VA scores greater than 4 approximated the 2% threshold commonly used to initiate anticoagulation in AF. Canadian Cardiovascular Society.
- 1 June 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (6) , 765-774
Risk for Stroke After Newly Diagnosed Atrial Fibrillation During Hospitalization for Other Primary Diagnoses
Atrial fibrillation (AF) that is first diagnosed during hospitalization for other causes can subside with resolution of the inciting stressor. To describe the risk for stroke after newly diagnosed AF during hospitalization for other causes. Population-based retrospective cohort study. Ontario, Canada. Patients aged 66 years or older discharged alive from the hospital between April 2013 and March 2023 with a first diagnosis of AF. Newly diagnosed AF during hospitalization for other causes, categorized into cardiac medical, noncardiac medical, cardiac surgical, and noncardiac surgical. The primary outcome was hospitalization for stroke. The cumulative incidence function was used to estimate crude incidence, censoring on anticoagulant dispensation. Inverse probability of censoring weights were used to account for informative censoring. Atrial fibrillation was diagnosed in 20 639 patients (mean age, 77.1 years; 58.1% male) while hospitalized for other causes: 8340 (40.4%) for noncardiac medical, 7097 (34.4%) for cardiac surgical, 3553 (17.2%) for noncardiac surgical, and 1649 (8.0%) for cardiac medical diagnoses. At 1 year, anticoagulants were being dispensed to 26.4% of patients with CHA2DS2-VA scores of 1 to 4 and 35.2% of those with CHA2DS2-VA scores of 5 to 8. The 1-year risk for stroke without anticoagulation was 1.3% (95% CI, 0.7% to 2.3%) for cardiac medical, 1.2% (CI, 0.9% to 1.5%) for noncardiac medical, 1.1% (CI, 0.8% to 1.7%) for noncardiac surgical, and 1.0% (CI, 0.7% to 1.3%) for cardiac surgical patients. Patients with CHA2DS2-VA scores of 1 to 4 had a 1-year stroke risk of 0.7% (CI, 0.6% to 1.0%) without anticoagulation, compared with 1.8% (CI, 1.4% to 2.2%) at CHA2DS2-VA scores of 5 to 8. Long-standing AF may have been misclassified as newly diagnosed, leading to overestimation of stroke risk. Among patients with newly diagnosed AF during hospitalization for other causes, a substantial proportion with low CHA2DS2-VA scores receive anticoagulation, with modest increases in this proportion at higher scores. The stroke risk in patients with CHA2DS2-VA scores greater than 4 approximated the 2% threshold commonly used to initiate anticoagulation in AF. Canadian Cardiovascular Society.
- 22 April 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (8) , e213478
Magnitude and Time-Course of Dementia Risk in Stroke Survivors
- 22 April 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (8) , e213478
Magnitude and Time-Course of Dementia Risk in Stroke Survivors
- 21 January 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (3) , 282-284
Driving Restrictions and Incapacitation Vulnerability Evaluation After ST-Segment–Elevation Myocardial Infarction: DRIVE-STEMI Study
- 21 January 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (3) , 282-284
Driving Restrictions and Incapacitation Vulnerability Evaluation After ST-Segment–Elevation Myocardial Infarction: DRIVE-STEMI Study